IntelliSyn selected as exclusive Med Chem partner for Epigenetix

July 15, 2012 – IntelliSyn selected as exclusive Med Chem partner for Epigenetix, a Miami-based biotechnology group focusing on novel epigenetic mechanisms for cancer and other indications. Epigenetix provides full medicinal chemistry design, synthesis, and DMPK support.